Davis A, Brogan A, Mellott CE, Fraysse J, Oglesby A. Cost-effectiveness of every two month Cabotegravir long-acting (CAB-LA) compared with daily oral Emtricitabine (FTC)/Tenofovir Disoproxil Fumarate (TDF) for pre-exposure Prophylaxis (PrEP) to prevent HIV-1 infection in the United States. Presented at the ISPOR 2022 Conference; May 10, 2022. Washington, DC. [abstract] Value Health. 2022 Jun; 25(6 S1).
Carrico J, La EM, Talbird SE, Chen YT, Nyaku MK, Carias C, Marshall GS, Roberts CS. Economic impact of routine childhood immunization in the 2017 United States birth cohort. Presented at the Virtual ISPOR Europe 2020 Conference; November 2020. [abstract] Value Health. 2020 Dec 1; 23(Supplement 2):S427. doi: 10.1016/j.jval.2020.08.039
Reed SD, Saltus CW, Getahun D, Schoendorf J, Armstrong MA, Peipert JF, Raine-Bennett TR, Ritchey ME, Ichikawa LE, Zhou X, Fassett MJ, Alabaster A, Xie F, Merchant M, Chiu VY, Shi JM, Frenz A-K, Im TM, Takhar HS, Lynen R, Asiimwe A, Anthony MS. Menorrhagia and risk of intrauterine device (IUD) expulsion and uterine perforation: results from the APEX IUD study. Presented at the Virtual 76th Scientific Congress of the American Society for Reproductive Medicine (ASRM); October 17, 2020. [abstract] Fertil Steril. 2020 Sep 1; 114(3 Suppl):e12. doi: 10.1016/j.fertnstert.2020.08.059
Herring W, Keenan A, Mauskopf J, Michael T, Wiegand F. The potential economic value of disease-modifying treatments in Alzheimer's disease: patient-level simulation of predementia symptom trajectories. Presented at the 2017 ISPOR 22nd Annual International Meeting; May 23, 2017. Boston, MA. [abstract] Value Health. 2017 May; 20(5):A12.
Thompson JR, Talbird SE, Mauskopf JA, Brogan AJ, Standaert B. Translating outcomes from a dynamic transmission model for vaccination to cost-effectiveness estimates: the impact of different analytic approaches on the results. Presented at the 2012 ISPOR 17th Annual International Meeting; June 6, 2012. Washington, DC. [abstract] Value Health. 2012 Jun; 15(4):A10.